tirzepatide trials once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Lilly says weight loss drug

Researchers who have used tirzepatide before starting retatrutide report that the transition requires careful dose management

obesity (BMI 30) or overweight (BMI 27) with at least one weight-related condition , such as high blood pressure, type 2 diabetes, or sleep apnoea

Lessai de phase 2, paru dans le New England Journal of Medicine en 2023, a document une perte de poids moyenne de 24,2 % du poids corporel sur 48 semaines chez des adultes obses ou en surpoids

Transporting long-chain fatty acids into the mitochondriayour cells' powerhousewhere the fats are oxidized to produce energy

Barnett C, Costill DL, Vukovich MD, Cole KJ, Goodpaster BH, Trappe SW, Fink WJ (1994) Effect of l-carnitine supplementation on muscle and blood carnitine content and lactate accumulation during high-intensity sprint cycling

Again, thinking about the risk-benefit ratio can help